Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114205 · ClinicalTrials.gov registry record · Phase 1
Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00114205 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 24 participants.
The verdict
NCT00114205, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Giving drugs, such as docetaxel, directly into the pleura after surgery to drain the pleural effusion may help keep fluid from building up again. PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of intrapleural docetaxel given after surgery in patients with malignant pleural effusion.
Interventions
- DRUG docetaxel
- PROCEDURE therapeutic thoracoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114205
The ClinicalTrials.gov registry entry for NCT00114205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00114205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00114205 about?
NCT00114205 is a clinical study titled "Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion". RATIONALE: Giving drugs, such as docetaxel, directly into the pleura after surgery to drain the pleural effusion may help keep fluid from building up again. PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of intrapleural docetaxel given after surgery in pat...
What is the current status of trial NCT00114205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2003-07.
What interventions are being tested in trial NCT00114205?
The interventions under investigation include: docetaxel (DRUG), therapeutic thoracoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT00114205?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.